Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Chemoterapie s nebo bez imunoterapie pro peritoneální mezoteliom

16. listopadu 2026 aktualizováno: National Cancer Institute (NCI)

Randomizovaná studie fáze 2 neoadjuvantní nebo paliativní chemoterapie s imunoterapií nebo bez imunoterapie pro peritoneální mezoteliom

This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

PRIMARY OBJECTIVE:

I. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior best response rate than carboplatin, pemetrexed and bevacizumab in patients with peritoneal mesothelioma as determined by Response Evaluation Criteria in Solid Tumors (RECIST).

SECONDARY OBJECTIVES:

I. To determine the safety, major pathologic response rates, and completeness of cytoreduction of patients treated with neoadjuvant carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab.

II. To determine the safety of patients treated with palliative carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab.

III. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior metabolic response rate than carboplatin, pemetrexed and bevacizumab as determined by Positron Emission Tomography (PET) Response Criteria in Solid Tumors.

IV. Explore the value that analysis of secondary computed tomography (CT) findings and quantitative fludeoxyglucose F-18 (FDG)-PET imaging adds to prognostic information and response assessment in this disease.

V. Determine the number of patients who were deemed to have unresectable disease who are able to undergo surgery following treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab due to dramatic response.

VI. To compare the progression-free survival and overall survival between arms. VII. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.

EXPLORATORY OBJECTIVE:

I. To determine whether blood-based biomarkers including our recently described cell-free chromosomal junctions, soluble mesothelin-related peptides and megakaryocyte potentiating factor correlate with clinical outcomes data (i.e. overall survival [OS], progression-free survival [PFS], recurrence, response, etc.).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive atezolizumab intravenously (IV) over 30-60 minutes, bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive atezolizumab IV over 30-60 minutes and bevacizumab IV on day 1 of each maintenance therapy cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive bevacizumab IV with or without atezolizumab IV over 30-60 minutes on day 1 of each maintenance therapy cycle at the discretion of the investigator. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study.

After completion of study treatment, patients are followed up every 6 months for up to 3 years.

Typ studie

Intervenční

Zápis (Odhadovaný)

66

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Arizona
      • Phoenix, Arizona, Spojené státy, 85054
        • Pozastaveno
        • Mayo Clinic Hospital in Arizona
    • Illinois
      • Chicago, Illinois, Spojené státy, 60637
        • Nábor
        • University of Chicago Comprehensive Cancer Center
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Hedy L. Kindler
      • Chicago, Illinois, Spojené státy, 60606
        • Nábor
        • Alliance for Clinical Trials in Oncology
        • Vrchní vyšetřovatel:
          • Aaron S. Mansfield
        • Kontakt:
      • Danville, Illinois, Spojené státy, 61832
        • Nábor
        • Carle at The Riverfront
        • Vrchní vyšetřovatel:
          • Suparna Mantha
        • Kontakt:
      • Effingham, Illinois, Spojené státy, 62401
        • Nábor
        • Carle Physician Group-Effingham
        • Vrchní vyšetřovatel:
          • Suparna Mantha
        • Kontakt:
      • Mattoon, Illinois, Spojené státy, 61938
        • Nábor
        • Carle Physician Group-Mattoon/Charleston
        • Vrchní vyšetřovatel:
          • Suparna Mantha
        • Kontakt:
      • Urbana, Illinois, Spojené státy, 61801
        • Nábor
        • Carle Cancer Center
        • Vrchní vyšetřovatel:
          • Suparna Mantha
        • Kontakt:
      • Urbana, Illinois, Spojené státy, 61801
        • Nábor
        • The Carle Foundation Hospital
        • Vrchní vyšetřovatel:
          • Suparna Mantha
        • Kontakt:
    • Kentucky
      • Lexington, Kentucky, Spojené státy, 40536
        • Aktivní, ne nábor
        • University of Kentucky/Markey Cancer Center
    • Minnesota
      • Bemidji, Minnesota, Spojené státy, 56601
      • Coon Rapids, Minnesota, Spojené státy, 55433
        • Nábor
        • Mercy Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Edina, Minnesota, Spojené státy, 55435
        • Nábor
        • Fairview Southdale Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Edina, Minnesota, Spojené státy, 55435
        • Nábor
        • Minnesota Oncology - Edina
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Fridley, Minnesota, Spojené státy, 55432
        • Aktivní, ne nábor
        • Unity Hospital
      • Minneapolis, Minnesota, Spojené státy, 55407
        • Nábor
        • Abbott-Northwestern Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Rochester, Minnesota, Spojené státy, 55905
        • Nábor
        • Mayo Clinic in Rochester
        • Kontakt:
          • Site Public Contact
          • Telefonní číslo: 855-776-0015
        • Vrchní vyšetřovatel:
          • Aaron S. Mansfield
      • Saint Louis Park, Minnesota, Spojené státy, 55416
        • Nábor
        • Park Nicollet Clinic - Saint Louis Park
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Saint Paul, Minnesota, Spojené státy, 55101
        • Nábor
        • Regions Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Saint Paul, Minnesota, Spojené státy, 55102
        • Nábor
        • United Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Willmar, Minnesota, Spojené státy, 56201
        • Nábor
        • Rice Memorial Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yan Ji
      • Worthington, Minnesota, Spojené státy, 56187
        • Nábor
        • Sanford Cancer Center Worthington
        • Vrchní vyšetřovatel:
          • Daniel Almquist
        • Kontakt:
          • Site Public Contact
          • Telefonní číslo: 605-312-3320
    • North Dakota
      • Bismarck, North Dakota, Spojené státy, 58501
      • Fargo, North Dakota, Spojené státy, 58122
      • Fargo, North Dakota, Spojené státy, 58122
    • Ohio
      • Columbus, Ohio, Spojené státy, 43210
        • Nábor
        • Ohio State University Comprehensive Cancer Center
        • Kontakt:
        • Vrchní vyšetřovatel:
          • John L. Hays
    • Oklahoma
      • Oklahoma City, Oklahoma, Spojené státy, 73104
        • Nábor
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Hassan Hatoum
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Spojené státy, 15232
        • Nábor
        • UPMC Hillman Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonní číslo: 412-647-8073
        • Vrchní vyšetřovatel:
          • Liza C. Villaruz
    • South Dakota
      • Sioux Falls, South Dakota, Spojené státy, 57104
      • Sioux Falls, South Dakota, Spojené státy, 57117-5134
    • Texas
      • Conroe, Texas, Spojené státy, 77384
        • Nábor
        • UT MD Anderson - The Woodlands
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kanwal P. Raghav
      • Houston, Texas, Spojené státy, 77030
        • Nábor
        • UT MD Anderson Cancer Center
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kanwal P. Raghav
      • Houston, Texas, Spojené státy, 77079
        • Nábor
        • UT MD Anderson - West Houston
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kanwal P. Raghav
      • League City, Texas, Spojené státy, 77573
        • Nábor
        • UT MD Anderson - League City
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kanwal P. Raghav
      • Sugar Land, Texas, Spojené státy, 77478
        • Nábor
        • UT MD Anderson - Sugar Land
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kanwal P. Raghav
    • Wisconsin
      • Appleton, Wisconsin, Spojené státy, 54911
        • Nábor
        • ThedaCare Regional Cancer Center
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Matthias Weiss
      • Eau Claire, Wisconsin, Spojené státy, 54701
      • Marshfield, Wisconsin, Spojené státy, 54449
      • Minocqua, Wisconsin, Spojené státy, 54548
      • Rice Lake, Wisconsin, Spojené státy, 54868
      • Stevens Point, Wisconsin, Spojené státy, 54482
      • Weston, Wisconsin, Spojené státy, 54476

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Physicians should consider whether any of the following may render the patient inappropriate for this protocol:

    • Psychiatric illness which would prevent the patient from giving informed consent

    • Medical conditions such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient

      • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
      • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
      • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
    • Patients with a "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for >= 3 years

  • In addition:

    • Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)

      • A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
  • Histologically or cytologically confirmed malignant peritoneal mesothelioma for which there has been no prior treatment. Given the indolent nature of well-differentiated papillary mesothelioma and multicystic mesothelioma, patients with these variants are not eligible for participation

  • Must have measurable disease per RECIST version (v) 1.1

  • Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 28 days prior to registration is required

  • Age >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  • Leukocytes >= 2,500/mm^3

  • Absolute neutrophil count (ANC) >= 1,500/mm^3

  • Platelet count >= 100,000/mm^3

  • Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

  • Total bilirubin =< 1.5 x upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)

  • Urine protein/creatinine (UPC) ratio < 1, or urine protein: =< 1+

  • No prior systemic therapy for peritoneal mesothelioma is allowed. No concurrent radiotherapy is allowed

  • No active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis, with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
    • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
  • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

    • Rash must cover < 10% of body surface area
    • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
    • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan

  • No prior allogeneic stem cell or solid organ transplantation

  • Central nervous system (CNS) metastases must have been treated with local therapy (surgery, radiation, ablation) with systemic steroids tapered to a physiologic dose (10 mg or prednisone equivalent or less)

  • Patients who have received live attenuated vaccines within 30 days of the first dose of trial treatment are eligible at the discretion of the investigator. All seasonal influenza vaccines and vaccines intended to prevent SARS-CoV-2 and coronavirus disease 2019 (COVID-19) are allowed

  • No history of inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)

  • No history of hypertensive crisis or hypertensive encephalopathy

  • No clinically significant cardiovascular disease, such as cerebrovascular accidents within 12 months prior to randomization, myocardial infarction within 12 months prior to randomization, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with study treatment

  • No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to randomization

  • No history of grade >= 4 venous thromboembolism

  • No history or evidence upon physical or neurological examination of central nervous system disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy

  • No history of grade >= 2 hemoptysis (defined as >= 2.5 mL of bright red blood per episode) within 1 month prior to screening

  • No history or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)

  • No major surgical procedure or significant traumatic injury within 28 days prior to initiation of study treatment (diagnostic laparoscopy is allowed as part of diagnosing peritoneal mesothelioma)

  • No core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to initiation of study treatment

  • Placement of a vascular access device should be at least 2 days prior to initiation of study treatment

  • No active infection requiring IV antibiotics at the time of initiation of study treatment

  • No history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization

  • No serious, non-healing wound, active ulcer, or untreated bone fracture

  • No other malignancy within 5 years prior to randomization, except for localized cancer in situ, such as basal or squamous cell skin cancer

  • Patients with a creatinine clearance between 45 and 79 mL/min should not use ibuprofen or other nonsteroidal anti-inflammatory drug (NSAIDs) for 2 days before, the day of, and 2 days following pemetrexed administration

  • No treatment with immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:

    • Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) may be eligible for the study
    • Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)

Patients receive atezolizumab IV over 30-60 minutes, bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive atezolizumab IV over 30-60 minutes and bevacizumab IV on day 1 of each maintenance therapy cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study.

Given IV

Ostatní jména:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatin
  • Paraplatin AQ
  • Paraplatina
  • Platinwas
  • Ribocarbo
  • JM8

Given IV

Ostatní jména:
  • Avastin
  • ABP 215
  • Anti-VEGF
  • Anti-VEGF humanizovaná monoklonální protilátka
  • Monoklonální protilátka proti VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab Biosimilar ABP 215
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar GB-222
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab Biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar Mvasi
  • Bevacizumab Biosimilar MYL-1402O
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab Biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • Bevacizumab Biosimilar Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilar
  • HD204
  • Imunoglobulin G1 (lidský-myší monoklonální rhuMab-VEGF gama-řetězcový anti-lidský vaskulární endoteliální růstový faktor), disulfid s lidským-myším monoklonálním lehkým řetězcem rhuMab-VEGF, dimer
  • Mvasi
  • MYL-1402O
  • Rekombinantní humanizovaná anti-VEGF monoklonální protilátka
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab Biosimilar QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilar
  • Bevacizumab Biosimilar BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-ekvi
  • Bevacizumab-maly
  • Bevacizumab-onbe
  • ČT P16
  • CTP16
  • Ekvidacentní
  • Onbevzi
  • Avzivi
  • Bevacizumab Biosimilar MB02
  • Bevacizumab-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • Oyavas
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given IV

Ostatní jména:
  • Alimta
  • LY231514
  • Disodná sůl kyseliny N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamové
  • Almita

Undergo CT scan

Ostatní jména:
  • ČT
  • KOČKA
  • CAT skenování
  • Počítačová axiální tomografie
  • Počítačová tomografie
  • CT vyšetření
  • tomografie
  • Počítačová axiální tomografie (postup)
  • Počítačová tomografie (CT).
  • Diagnostické skenování CAT
  • Typ služby diagnostického skenování CAT

Undergo PET scan

Ostatní jména:
  • Lékařské zobrazování, pozitronová emisní tomografie
  • PET
  • PET skenování
  • Skenování pozitronové emisní tomografie
  • Pozitronová emisní tomografie
  • PT
  • Pozitronová emisní tomografie (postup)

Given IV

Ostatní jména:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RG 7446
  • RO 5541267
  • RO-5541267

Undergo blood and tissue sample collection

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Undergo surgery

Ostatní jména:
  • Cytoredukce

Undergo HIPEC

Ostatní jména:
  • HIPEC
Aktivní komparátor: Arm II (carboplatin, pemetrexed, bevacizumab)

Patients receive bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive bevacizumab IV with or without atezolizumab IV over 30-60 minutes on day 1 of each maintenance therapy cycle at the discretion of the investigator. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study.

Given IV

Ostatní jména:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatin
  • Paraplatin AQ
  • Paraplatina
  • Platinwas
  • Ribocarbo
  • JM8

Given IV

Ostatní jména:
  • Avastin
  • ABP 215
  • Anti-VEGF
  • Anti-VEGF humanizovaná monoklonální protilátka
  • Monoklonální protilátka proti VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab Biosimilar ABP 215
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar GB-222
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab Biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar Mvasi
  • Bevacizumab Biosimilar MYL-1402O
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab Biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • Bevacizumab Biosimilar Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilar
  • HD204
  • Imunoglobulin G1 (lidský-myší monoklonální rhuMab-VEGF gama-řetězcový anti-lidský vaskulární endoteliální růstový faktor), disulfid s lidským-myším monoklonálním lehkým řetězcem rhuMab-VEGF, dimer
  • Mvasi
  • MYL-1402O
  • Rekombinantní humanizovaná anti-VEGF monoklonální protilátka
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab Biosimilar QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilar
  • Bevacizumab Biosimilar BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-ekvi
  • Bevacizumab-maly
  • Bevacizumab-onbe
  • ČT P16
  • CTP16
  • Ekvidacentní
  • Onbevzi
  • Avzivi
  • Bevacizumab Biosimilar MB02
  • Bevacizumab-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • Oyavas
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given IV

Ostatní jména:
  • Alimta
  • LY231514
  • Disodná sůl kyseliny N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamové
  • Almita

Undergo CT scan

Ostatní jména:
  • ČT
  • KOČKA
  • CAT skenování
  • Počítačová axiální tomografie
  • Počítačová tomografie
  • CT vyšetření
  • tomografie
  • Počítačová axiální tomografie (postup)
  • Počítačová tomografie (CT).
  • Diagnostické skenování CAT
  • Typ služby diagnostického skenování CAT

Undergo PET scan

Ostatní jména:
  • Lékařské zobrazování, pozitronová emisní tomografie
  • PET
  • PET skenování
  • Skenování pozitronové emisní tomografie
  • Pozitronová emisní tomografie
  • PT
  • Pozitronová emisní tomografie (postup)

Undergo blood and tissue sample collection

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Undergo surgery

Ostatní jména:
  • Cytoredukce

Undergo HIPEC

Ostatní jména:
  • HIPEC

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Response rate
Časové okno: Up to 4 years after study activation

Will be compared between arms.

Up to 4 years after study activation

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Major pathologic response rate
Časové okno: Up to 3 years

The proportion of patients with a pathologic response will be calculated and compared between arms and 95% confidence intervals reported. The chi-square test will be used to compare the rates between arms.

Up to 3 years
Completeness of cytoreduction
Časové okno: Up to 3 years

Will be estimated.

Up to 3 years
Conversion rate to surgical resection among those not deemed to be surgical candidates
Časové okno: Up to 3 years

Will estimate the conversion rate to surgical resection among those not deemed to be surgical candidates prior to treatment and provide the 95% confidence interval as well.

Up to 3 years
Progression-free survival (PFS)
Časové okno: From study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on Response Evaluation Criteria in Solid Tumors 1.1 criteria, assessed up to 3 years

Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.

From study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on Response Evaluation Criteria in Solid Tumors 1.1 criteria, assessed up to 3 years
Overall survival
Časové okno: From study entry to death from any cause, assessed up to 3 years

Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.

From study entry to death from any cause, assessed up to 3 years
Incidence of adverse events
Časové okno: Up to 3 years

The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test.

Up to 3 years

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Soluble mesothelin-related peptides (SMRP) and megakaryocyte potentiating factor (MPF)
Časové okno: Up to 3 years

Will assess the association between two continuous biomarkers, MPF and SMRP, and best response to treatment prior to surgery, defined as response (complete response/partial response) versus no response (stable disease/progressive disease). Two separate logistic regression models will be used, one for each biomarker, with response status as the binary outcome and MPF or SMRP as the independent variable. The significance of the association will be evaluated using the Wald test from each model at a significance level of 0.05. Each biomarker will be assessed for skewness via visual inspection of histograms. If MPF or SMRP values appear markedly non-normal, will apply a logarithmic transformation to reduce skewness. To address zero values, a constant of 0.1 will be added to all observations before log transformation. Will explore the association of MPF and SMRP with the primary and secondary endpoints with and without accounting for treatment arm effects.

Up to 3 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Aaron S Mansfield, Alliance for Clinical Trials in Oncology

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

22. března 2022

Primární dokončení (Odhadovaný)

1. srpna 2027

Dokončení studie (Odhadovaný)

1. srpna 2027

Termíny zápisu do studia

První předloženo

11. srpna 2021

První předloženo, které splnilo kritéria kontroly kvality

11. srpna 2021

První zveřejněno (Aktuální)

12. srpna 2021

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

16. listopadu 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • NCI-2021-08573
  • U10CA180821 (Grant/smlouva NIH USA)
  • NCI-2021-08573 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
  • A092001 (Jiný identifikátor: CTEP)
  • A092001 (Jiný identifikátor: Alliance for Clinical Trials in Oncology)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .